DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Mobile PET relieves hardship for rural cancer patients Mobile PET isn't just good medicine, it's good business

In nuclear medicine, scanners get more sensitive, software more specific What's new in PET and SPECT?

US suppliers to join the Mo-99 market, high-energy materials gaining traction Radiopharmaceutical supply chain update

Navigating the molecular imaging market Purchasing insights from the experts at MD Buyline

Assessing the state of Alzheimer’s imaging The battle against neuro-degenerative disease wages on

Absolute Imaging Solutions acquires Northeast Electronics Facilitates push into East Coast market

Eden Radioisotopes scores funding for isotope reactor production Will primarily produce Mo-99

SHINE secures rights to new method for Lutetium-177 production Generate Lu-177 at greater speed and scale

FDA gives green light to new United Imaging PET/MR scanner The uPMR 790 HD TOF performs total-body scans within 20 minutes

FDA reminder for properly eluting rubidium 82 generators prompted by 'recent incidents' Using incorrect solutions puts patients at risk

Over 80 percent accurate

New PET imaging agent predicts tumor response to lung cancer drug

by Lauren Dubinsky , Senior Reporter
A team at the Stanford University School of Medicine developed a PET imaging agent that can predict a tumor’s response to a widely-used lung cancer drug with more than 80 percent accuracy.

“This would lead to better patient management for the oncologist,” Dr. Sanjiv Gambhir, professor and chair of radiology at Stanford, told HCB News. “For the patient it would mean more confidence that their drug is actually working — if it’s not, then not much time is lost before moving to a new drug.”

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Once injected, the F-MPG tracer travels throughout the patient’s body and attaches to any mutated epidermal growth factor proteins. It then emits gamma rays to reveal the location and mutational details of the protein.

A patient who is likely to respond well to the cancer drug will have a PET scan that shows a high signal from the tracer. Those who show low signals are not likely to respond to treatment, so other treatment options need to be considered.

Gambhir said that some people wonder whether the oncologist can prescribe the drug and just wait to see if the tumor shrinks. If the therapy isn’t effective, the tumor will continue to grow and also become more molecularly complex, which makes it harder to treat with the next round of therapy.

Biopsies can inform oncologists what mutations are present, but they can’t accurately capture the spectrum of mutations present in the mass. They are even less likely to characterize the mutations present in multiple tumors such as ones that have spread to other parts of the body.

Gambhir explained that this new F-MPG PET imaging technique is like taking a biopsy of the entire body. It provides more comprehensive information on the mutational status of the primary tumor.

The research team conducted a clinical trial at Harbin Medical University in China to test the imaging agent. Seventy-five participants were injected with F-MPG and the using PET scans the researchers monitored which tumors lit up and which had a low signal.

They found that over 80 percent of the participants had a positive response to the target drug, which means the tumor shrank or growth slowed. However, 6 percent of the participants who lacked PET evidence of the mutation did benefit from the drug.

The next step is to recruit more participants for a larger trial. Since F-MPG is only approved for use in China, future studies will continue at Harbin Medical University.

When asked if F-MPG will eventually become the standard for predicting lung cancer treatment efficacy, Gambhir said he thinks it will take at least three to five years for that to happen.

“We will need to do a multi-center prospective trial and build a lot more evidence that this new PET tracer can work as predicted in the 75 patients studied to date,” he added.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.